Five previous meta-analyses reported that an SGLT2i as an add-on therapy to insulin is effective in improving glycemic and blood pressure control and decreasing body weight and total daily insulin dose in patients with T1DM [35, 40, 58–60]. The gene discussed is INS; the disease is type 1 diabetes mellitus.